Event JSON
{
"id": "4542b46f443ca0f8bae198bfb50ecb0797f4f028920ea420bb584eb7a772f8e6",
"pubkey": "71d38b07e4b336654573c9d1543ef2fe067ef2e2ca348e6db0effd140e3f2a64",
"created_at": 1694087349,
"kind": 1,
"tags": [
[
"p",
"8599d6abea70cc86ed7a21ac5b2d4395dd45f31215d34a86cb4814843c174388",
"wss://relay.mostr.pub"
],
[
"p",
"c71a5284689572bfd0beef4cbb9b331e25b49be5535123c2692f4a13e17c0a48",
"wss://relay.mostr.pub"
],
[
"e",
"6b9cabfe3105e92cb24e3c483cb4044a62d457a031901967064e09a08110f057",
"wss://relay.mostr.pub",
"reply"
],
[
"proxy",
"https://mstdn.science/users/cian/statuses/111023708543140333",
"activitypub"
]
],
"content": "nostr:npub1skvad2l2wrxgdmt6yxk9kt2rjhw5tucjzhf54pktfq2gg0qhgwyqdlaky3 thanks, that makes sense if we want to treat at a molecular level. But the worry is that for many disorders with complicated genetics (eg ASD, schizophrenia), or extremely rare genetic conditions, we may not have the knowledge or tools or money needed to make those low-level interventions.\n\nWe wrote a review previously arguing that in those cases, degeneracy may open up the chance for higher-level eg circuit treatments\n\nhttps://www.sciencedirect.com/science/article/pii/S0959438821000787",
"sig": "a942d4005929fa72685997bc1d99845441299348445c172d01c57537bd80c1c05c97fc758363ced6363e0a73c0d8a96f19b6bfbae60a7946e9c70a4cede39298"
}